| Literature DB >> 28718949 |
Rafael Calais Gaspar1, José Diego Botezelli1, Gabriel Keine Kuga2, Vitor Rosetto Muñoz1, Andressa Coope3, Rodrigo Martins Pereira1, Adelino Sanchez Ramos da Silva4, Dennys Esper Cintra1,5, Leandro Pereira de Moura1,5,6, Eduardo Rochete Ropelle1,5,6, José Rodrigo Pauli1,5,6.
Abstract
Preclinical Research Metabolic disorders are responsible for more than 60% of all deaths worldwide. Calcitriol or vitamin D (vitD) deficiency is associated with a large proportion of these diseases is an important therapeutic target for exploration. This study evaluated the administration of high doses of vitD (3000 IU/kg) in obese and insulin-resistant C57BL/6J mice. Our results demonstrated that although high doses of vitD provided metabolic benefits such as increased insulin sensitivity and decreased body mass, this was associated with significant damage in the kidneys of obese mice. These findings support the role of vitD as a therapeutic strategy against metabolic disorders. However, caution is required with the dose administrated, and the renal damage associated still needs to be investigated. Drug Dev Res 78 : 203-209, 2017.Entities:
Keywords: insulin; obesity; vitamin D
Mesh:
Substances:
Year: 2017 PMID: 28718949 DOI: 10.1002/ddr.21394
Source DB: PubMed Journal: Drug Dev Res ISSN: 0272-4391 Impact factor: 4.360